Key result
Malignant hypertension remains a clinically relevant and challenging entity, with improving prognosis but no significant change in incidence, often diagnosed only when target organ damage occurs.
Malignant hypertension remains a clinically relevant and challenging condition that must be considered during the assessment of patients with poorly controlled hypertension.
Answers are grounded in this paper and cite their sources.
Early detection of malignant hypertension before organ damage warrants renewed clinical focus; leaves open whether incidence trends can be altered.
Malignant or accelerated hypertension is the most severe form of hypertension, defined clinically by very high blood pressure (diastolic above 130 mm Hg) accompanied by bilateral retinal hemorrhages and/or exudates, with or without papilledema. The aim of this review is to discuss if malignant hypertension still poses a clinically relevant entity and to highlight the diagnostic challenges of this form of hypertension. The substantial improvement in prognosis in patients with malignant hypertension over the last decades is well documented, but there is no strong evidence to suggest a significant change in its incidence. In fact, with the growing population and improving life expectancy, malignant hypertension is likely to become even more prevalent worldwide, especially in the developing countries with less advanced health care services. Despite simple diagnostic criteria of malignant hypertension, the diagnoses may be difficult in many patients. Malignant hypertension patients often have the diagnosis established only when the target organ damage occur. Furthermore, retrospective diagnosis is problematic, as malignant hypertensive retinopathy gradually resolves over a relatively short period of time, while persistent target organ damage will, however, lead to the development of complications and much poorer prognosis than in nonmalignant hypertension patients. Certainly, malignant hypertension still poses a clinically relevant and challenging form of hypertension and its possibility should be always considered during the assessment of patients with poorly controlled hypertension.
No takes yet. Share an insight, caveat, or question.
Shantsila et al. (2017) conducted a review in Malignant hypertension. Malignant hypertension was evaluated. Malignant hypertension remains a clinically relevant and challenging entity, with improving prognosis but no significant change in incidence, often diagnosed only when target organ damage occurs.
Synapse has enriched 10 related papers. Consider them for comparative context: